{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T06:31:24Z","timestamp":1793341884599,"version":"4.5.0"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:00:00Z","timestamp":1769212800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001821","name":"Vienna Science and Technology Fund","doi-asserted-by":"publisher","award":["10.47379\/LS20081"],"award-info":[{"award-number":["10.47379\/LS20081"]}],"id":[{"id":"10.13039\/501100001821","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,30]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Antibody-mediated rejection (AMR) is among the leading causes of kidney transplant attrition. Traditional AMR therapy was based on interventional studies that were small and often uncontrolled. Although a blockade of the interleukin (IL)-6 pathway failed to prevent allograft loss in a phase 3 trial, anecdotal evidence had previously suggested potential benefit. Likewise, anti-CD20 antibodies have not been shown to improve AMR outcomes in terms of graft survival. Imlifidase, which cleaves all immunoglobulin Gs, and hence also all donor-specific antibodies, showed a higher rate of graft loss in the experimental group of an AMR study. Terminal complement inhibitors showed inconsistent efficacy in underpowered trials; currently, C3 inhibitors are a promising focus for complement-targeted strategies against AMR. Anti-CD38 antibodies currently represent the most promising novel therapy option for AMR based on encouraging phase 2 study results. We furthermore discuss genetically engineered CD38 knock-out multitarget natural killer cells, expressing anti-B cell maturation antigen (BCMA) CAR, IL-15RF and hnCD16, administered in combination with daratumumab (anti-CD38) in this context. This approach represents a cheaper and safer alternative to chimeric HLA antigen receptor (CHAR) T cell therapy. CHAR T cells showed a high specificity in recognizing their respective target anti-HLA class I B cell receptors in vitro. Quantitative results from in vivo trials are pending. Likewise, we hypothesize the use of bi-specific T cell engagers such as CD19 blinatumomab or BCMA teclistamab for the treatment of AMR. In addition, clinical studies investigating conversion from calcineurin inhibitors to co-stimulation therapies such as anti-CD40L antibodies may reduce dnDSAs and AMR. In summary, anti-CD38 antibodies currently constitute the drug class with the strongest evidence for AMR treatment. To date, most CD38 antibodies have been shown to be safe, even after several years of administration in patients with multiple myeloma.<\/jats:p>","DOI":"10.1093\/ndt\/gfag011","type":"journal-article","created":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T12:41:31Z","timestamp":1769258491000},"page":"1950-1955","source":"Crossref","is-referenced-by-count":1,"title":["Trends in nephrology: from nihilism to targeted treatment of antibody-mediated rejection"],"prefix":"10.1093","volume":"41","author":[{"given":"Josef Filip","family":"Pickl","sequence":"first","affiliation":[{"name":"Division of Nephrology, Medical University of Vienna Department of Internal Medicine, , Vienna ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7544-6275","authenticated-orcid":false,"given":"Rainer","family":"Oberbauer","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Medical University of Vienna Department of Internal Medicine, , Vienna ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,24]]},"reference":[{"key":"2026103001463812600_bib1","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/j.1600-6143.2011.03840.x","article-title":"Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence","volume":"12","author":"Sellar\u00e9s","year":"2012","journal-title":"Am J Transplant"},{"key":"2026103001463812600_bib2","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.ajt.2023.10.016","article-title":"The Banff 2022 Kidney Meeting Report: reappraisal of microvascular inflammation and the role of biopsy-based transcript diagnostics","volume":"24","author":"Naesens","year":"2024","journal-title":"Am J Transplant"},{"key":"2026103001463812600_bib3","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1097\/TP.0000000000003095","article-title":"Recommended treatment for antibody-mediated rejection after kidney transplantation: the 2019 Expert Consensus from the Transplantion Society Working Group","volume":"104","author":"Schinstock","year":"2020","journal-title":"Transplantation"},{"key":"2026103001463812600_bib4","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.kint.2025.04.023","article-title":"A randomized controlled trial of intravenous immunoglobulin vs standard of care for the treatment of chronic active antibody-mediated rejection in kidney transplant recipients","volume":"108","author":"Mulley","year":"2025","journal-title":"Kidney Int"},{"key":"2026103001463812600_bib5","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1097\/TP.0000000000002049","article-title":"The treatment of antibody-mediated rejection in kidney transplantation: an updated systematic review and meta-analysis","volume":"102","author":"Wan","year":"2018","journal-title":"Transplantation"},{"key":"2026103001463812600_bib6","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1681\/ASN.2017070818","article-title":"A randomized trial of bortezomib in late antibody-mediated kidney transplant rejection","volume":"29","author":"Eskandary","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"2026103001463812600_bib7","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1056\/NEJMoa1612567","article-title":"IgG endopeptidase in highly sensitized patients undergoing transplantation","volume":"377","author":"Jordan","year":"2017","journal-title":"N Engl J Med"},{"key":"2026103001463812600_bib8","doi-asserted-by":"publisher","first-page":"e15383","DOI":"10.1111\/ctr.15383","article-title":"A randomized trial comparing imlifidase to plasmapheresis in kidney transplant recipients with antibody-mediated rejection","volume":"38","author":"Halleck","year":"2024","journal-title":"Clin Transplant"},{"key":"2026103001463812600_bib9","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1097\/TP.0000000000000592","article-title":"A phase I\/II placebo-controlled trial of C1-inhibitor for prevention of antibody-mediated rejection in HLA sensitized patients","volume":"99","author":"Vo","year":"2015","journal-title":"Transplantation"},{"key":"2026103001463812600_bib10","doi-asserted-by":"publisher","first-page":"5456","DOI":"10.1038\/s41467-021-25745-7","article-title":"C3 complement inhibition prevents antibody-mediated rejection and prolongs renal allograft survival in sensitized non-human primates","volume":"12","author":"Schmitz","year":"2021","journal-title":"Nat Commun"},{"key":"2026103001463812600_bib11","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ekir.2024.09.030","article-title":"Efficacy and safety of pegcetacoplan in kidney transplant recipients with recurrent complement 3 glomerulopathy or primary immune complex membranoproliferative glomerulonephritis","volume":"10","author":"Bomback","year":"2025","journal-title":"Kidney Int Rep"},{"key":"2026103001463812600_bib12","doi-asserted-by":"publisher","first-page":"2052658","DOI":"10.1080\/21645515.2022.2052658","article-title":"Anti CD38 monoclonal antibodies for multiple myeloma treatment","volume":"18","author":"Gozzetti","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"2026103001463812600_bib13","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa2400763","article-title":"A randomized phase 2 trial of felzartamab in antibody-mediated rejection","volume":"391","author":"Mayer","year":"2024","journal-title":"N Engl J Med"},{"key":"2026103001463812600_bib14","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1681\/ASN.0000000000000287","article-title":"Isatuximab monotherapy for desensitization in highly sensitized patients awaiting kidney transplant","volume":"35","author":"Vincenti","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"2026103001463812600_bib15","doi-asserted-by":"publisher","first-page":"14343","DOI":"10.3389\/ti.2025.14343","article-title":"Targeting CD38 in antibody-mediated rejection","volume":"38","author":"Mayer","year":"2025","journal-title":"Transpl Int"},{"key":"2026103001463812600_bib16","doi-asserted-by":"publisher","first-page":"3506","DOI":"10.1016\/j.ekir.2025.07.009","article-title":"Anti-CD38 daratumumab treatment of chronic active antibody-mediated kidney allograft rejection","volume":"10","author":"Lye","year":"2025","journal-title":"Kidney Int Rep"},{"key":"2026103001463812600_bib17","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1038\/s41591-025-03653-3","article-title":"Effect of felzartamab on the molecular phenotype of antibody-mediated rejection in kidney transplant biopsies","volume":"31","author":"Diebold","year":"2025","journal-title":"Nat Med"},{"key":"2026103001463812600_bib18","doi-asserted-by":"publisher","first-page":"100043","DOI":"10.1016\/j.bneo.2024.100043","article-title":"Phase 1b study of the anti-CD38 antibody mezagitamab in patients with relapsed\/refractory multiple myeloma","volume":"1","author":"Krishnan","year":"2024","journal-title":"Blood Neoplasia"},{"key":"2026103001463812600_bib19","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1182\/blood-2019-131373","article-title":"FT576: a novel multiplexed engineered off-the-shelf natural killer cell immunotherapy for the dual-targeting of CD38 and Bcma for the treatment of multiple myeloma","volume":"134","author":"Bjordahl","year":"2019","journal-title":"Blood"},{"key":"2026103001463812600_bib20","doi-asserted-by":"publisher","first-page":"4586","DOI":"10.1182\/blood-2022-166994","article-title":"Interim phase I clinical data of FT576 as monotherapy and in combination with daratumumab in subjects with relapsed\/refractory multiple myeloma","volume":"140","author":"Dhakal","year":"2022","journal-title":"Blood"},{"key":"2026103001463812600_bib21","doi-asserted-by":"publisher","first-page":"13209","DOI":"10.3389\/ti.2024.13209","article-title":"Natural killer cell presence in antibody-mediated rejection","volume":"37","author":"Diebold","year":"2024","journal-title":"Transpl Int"},{"key":"2026103001463812600_bib22","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"key":"2026103001463812600_bib23","doi-asserted-by":"publisher","DOI":"10.1201\/9781315533247","volume-title":"Janeway\u2019s Immunobiology","author":"Murphy","year":"2016","edition":"9th edn."},{"key":"2026103001463812600_bib24","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.ymthe.2025.01.009","article-title":"Depletion of alloreactive B cells by drug-resistant chimeric alloantigen receptor T cells to prevent transplant rejection","volume":"33","author":"Dragon","year":"2025","journal-title":"Mol Ther"},{"key":"2026103001463812600_bib25","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1111\/tan.15156","article-title":"Chimeric HLA antibody receptor T cells for targeted therapy of antibody-mediated rejection in transplantation","volume":"102","author":"Betriu","year":"2023","journal-title":"HLA"},{"key":"2026103001463812600_bib26","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1111\/tan.15146","article-title":"Chimeric HLA antibody receptor T cells to target HLA-specific B cells in solid organ transplantation","volume":"102","author":"Gille","year":"2023","journal-title":"HLA"},{"key":"2026103001463812600_bib27","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"key":"2026103001463812600_bib28","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"key":"2026103001463812600_bib29","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"key":"2026103001463812600_bib30","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1186\/ar3909","article-title":"Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity","volume":"14","author":"Mei","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"2026103001463812600_bib31","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s00277-018-3495-2","article-title":"Efficacy and safety of blinatumomab treatment in adult Korean patients with relapsed\/refractory acute lymphoblastic leukemia on behalf of the Korean Society of Hematology ALL Working Party","volume":"98","author":"Jung","year":"2019","journal-title":"Ann Hematol"},{"key":"2026103001463812600_bib32","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"2026103001463812600_bib33","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1056\/NEJMoa1506027","article-title":"Belatacept and long-term outcomes in kidney transplantation","volume":"374","author":"Vincenti","year":"2016","journal-title":"N Engl J Med"},{"key":"2026103001463812600_bib34","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1126\/science.ade6949","article-title":"Switching off autoimmunity","volume":"385","author":"Laman","year":"2024","journal-title":"Science"},{"key":"2026103001463812600_bib35","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1056\/NEJMoa2309439","article-title":"Inhibition of CD40L with frexalimab in multiple sclerosis","volume":"390","author":"Vermersch","year":"2024","journal-title":"N Engl J Med"},{"key":"2026103001463812600_bib36","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1111\/j.1432-2277.2011.01223.x","article-title":"Costimulatory blockade with mTor inhibition abrogates effector T-cell responses allowing regulatory T-cell survival in renal transplantation","volume":"24","author":"Bestard","year":"2011","journal-title":"Transpl Int"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfag011\/66564632\/gfag011.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/41\/11\/1950\/66564632\/gfag011.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/41\/11\/1950\/66564632\/gfag011.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T05:46:42Z","timestamp":1793339202000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/41\/11\/1950\/8440141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,24]]},"references-count":36,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,1,24]]},"published-print":{"date-parts":[[2026,10,30]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfag011","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,11]]},"published":{"date-parts":[[2026,1,24]]}}}